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ABSTRACT
Background    Bofutsushosan is a well known Kampo, 
traditional Japanese medicine, based on ancient Chinese 
medicine mainly used in the treatment of hypercholes-
terolemia in Japan. We selected two Kampo formulas, 
Boiogito and Keishibukuryogan mainly used in the 
treatment of hypercholesterolemia in China to compare 
with Bofutsushosan and cholesterol absorption inhibitor 
ezetimibe. 
Methods    Hypercholesterolemia and fatty liver were 
induced by high cholesterol (containing 2% cholesterol 
and 0.5% cholic acid) diet in male Wistar rats for 6 and 
12 weeks. Kampo formulas Boiogito, Bofutsushosan, 
Keishibukuryogan and ezetimibe were added to the 
high-cholesterol diet, respectively. After 6 and 12 weeks, 
body and liver weights, blood chemistry, cholesterol 
concentrations, fat-related and inflammatory-related fac-
tors were examined.
Results    High-cholesterol diet increased body and 
liver weights, and serum cholesterol concentrations. 
Boiogito and ezetimibe improved them. Serum ICAM-
1 and RBP4 were increased in the high cholesterol diet 
group. Boiogito and ezetimibe improved them too. In 
the histological examinations of liver and adipose tis-
sues, we observed a significant improvement after treat-
ment. Immunostaining expression of ICAM-1 in aorta 
was improved by Boiogito, Bofutsushosan, Keishibuku-
ryogan and ezetimibe. The mRNA expression of RBP4, 
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Abbreviations: ALP, alkaline phosphatase; ALT, alanine amino-
transferase; BOT, Boiogito; BTS, Bofutsushosan; C, control group; 
CFABP, cutaneous fatty acid-binding protein; CVD, cardiovascu-
lar disease; H, high-cholesterol diet group; HA, high-cholesterol 
diet with Boiogito group; HB, high-cholesterol diet with Bofutsu-
shosan group; HC, high-cholesterol diet with Keishibukuryogan 
group; HDL-C, high-density lipoprotein cholesterol; HE, high-
cholesterol diet with ezetimibe group; HFABP, heart fatty acid-
binding protein; ICAM-1, intercellular adhesion molecule-1; 
KBG, Keishibukuryogan; LDL-C, low-density lipoprotein choles-
terol; MCP1, monocyte chemoattractant protein-1; NAFLD, non-
alcoholic fatty liver disease; RBP4, retinol-binding protein 4; TC, 
total cholesterol; VEC, vascular endothelial cells 
HFABP, CFABP, MCP1 and CCR2 in liver and adipose 
tissue were decreased by Boiogito and ezetimibe.  
Conclusion    Boiogito has a protective effect on the 
progression of hypercholesterolemia and fatty liver in-
duced by high-cholesterol diet in rats and more effective 
than Bofutsushosan and Keishibukuryogan. The lipid-
lowering effect of Boiogito is not stronger than ezeti-
mibe. But the anti-inflammatory (MCP1, CCR2) and 
anti-arteriosclerotic (ICAM-1) effects of Boiogito are 
more potent than ezetimibe. 
 
Key words    Bofutsushosan; Boiogito; Keishibukuryo-
gan; fatty liver; hypercholesterolemia 
  
Hypercholesterolemia is one of the major risk factors 
for many cardiovascular diseases, such as atheroscle-
rosis, hypertension and myocardial infarction.1, 2 Non-
alcoholic fatty liver disease (NAFLD) is common in the 
general population, and it occurs even more frequently 
in patients with hypercholesterolemia.3, 4 Patients with 
NAFLD have a high risk of cardiovascular disease 
(CVD).5 In addition, NAFLD is often associated with 
atherosclerotic signs including the presence of carotid 
plaques6 and coronary arterial calcification.7, 8
 It is generally believed that the occurrence and de-
velopment of hypercholesterolemia have significantly 
correlation to lipid metabolism-related genes, such 
as retinol-binding protein 4 (RBP4), heart fatty acid-
binding protein (HFABP), cutaneous fatty acid-binding 
protein (CFABP).9, 10 RBP4, a protein secreted by hepa-
tocytes and adipose tissue, is closely related to hyper-
cholesterolemia and NAFLD.11 HFABP and CFABP 
belongs to FABPs family which may play a broad role in 
cellular fatty acid metabolism.12 In addition to lipid me-
tabolism-related genes, inflammatory cytokines are as-
sociated with hypercholesterolemia. Engström et al. have 
supported the view that inflammation could be a risk 
factor for developing hypercholesterolemia.13 Monocyte 
chemoattractant protein-1 (MCP-1) and its receptor CC 
chemokine receptor 2 (CCR2) are important inflamma-
tory chemokines linked with hypercholesterolemia.14, 15 
Intercellular adhesion molecule-1 (ICAM-1) can promote 
the development and progression of atherosclerosis.16 
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Therefore, it is a simple and convenient method to detect 
hypercholesterolemia by monitoring RBP4, C-FABP, H-
FABP, MCP1, CCR2, ICAM-1 expression.
 Bofutsushosan (BTS), Boiogito (BOT) and Keishi-
bukuryogan (KBG) are well-known Japanese Kampo 
and Chinese traditional herbal medicines which are used 
to improve obesity.17, 18 BTS has been reported to inhibit 
atherosclerosis,19 obesity,17, 18, 20 hypertension17 and hy-
perglycemia.21 BOT and KBG are also Kampo prepara-
tions which have been used in patients with obesity.22, 23 
However, pharmacological evidence for the effects of 
treatment of NAFLD of BOT and KBG still remains 
obscure. Using the well-established experimental model 
of high-cholesterol diet in rats, we compared the phar-
macological efficacies of BOT, BTS and KBG. 
MATERIALS AND METHODS
Rats and feeding method
Sixty male Wistar rats aged 8-weeks (purchased from 
Shimizu Laboratory Supplies, Kyoto, Japan) were kept 
in an air-conditioned room at 25 ˚C with 55% humidity 
and given standard chow. After 3 days of acclimation, 
the rats were divided into 6 groups: control group (C, 
n = 10), high-cholesterol diet group (H, n = 10), high-
cholesterol diet with Kampo formula BOT group (HA, 
n = 10), high-cholesterol diet with Kampo formula BTS 
group (HB, n = 10), high-cholesterol diet with Kampo 
formula KBG group (HC, n = 10), high-cholesterol diet 
with ezetimibe group (HE, n = 10). The rats in each 
group were numbered from 1 to 10. Group C was fed 
a standard rat diet (CE-2; Japan Clea, Tokyo, Japan). A 
high-cholesterol diet11, 24 was supplied for Group H; it 
was prepared by adding 2% cholesterol and 0.5% cholic 
acid to the standard diet. The high-cholesterol diets with 
BOT, BTS or KBG were made by adding 1% extract for-
mulations of BOT, BTS or KBG to the high-cholesterol 
diet, respectively. These Kampo extract formulations 
were generous gift from Tsumura (Tokyo, Japan). The 
high-cholesterol diet with ezetimibe was made by add-
ing 0.0006% of ezetimibe (LKT laboratories, St Paul, 
MN). The amount of feed for each rat was regulated 
to 25 g/day and water was supplied ad libitum. Body 
weights, systolic and diastolic blood pressure and heart 
rate were measured weekly. Blood pressure and heart 
rate were measured by a noninvasive computerized tail-
cuff method (BP-98A; Softron, Tokyo).
 
Sample collection
On days 42 and 84, 5 rats of each group in the order of 
how they were numbered were sacrificed by collecting 
blood from the heart under pentobarbital anesthesia af-
ter fasting for 12 h. Liver tissue, adipose tissue around 
the left kidney and abdominal aorta were removed, 
and then portions of the samples were stored in a 10% 
formalin solution for hematoxylin-eosin staining and 
oil red O staining.25 The remaining samples were im-
mediately transferred into EP tubes containing 500 μL 
of RNA later (Ambion, Austin, TX), quickly frozen in 
liquid nitrogen, and stored at –80 ˚C. Serum levels of to-
tal cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C), 
triglyceride, blood sugar, creatinine, total bilirubin, ala-
nine aminotransferase (ALT) and alkaline phosphatase 
(ALP) were analyzed for rats using an auto analyzer at 
an accredited clinical laboratory (SRL, Tokyo).
 
ICAM-1 and RBP4
Serum samples were applied for an enzyme-linked 
immunosorbent assay (ELISA) of ICAM-1 (R＆D, 
Minneapolis, MN) and RBP4 (Aviscera Bioscience, CA) 
according to the manufacturer’s instructions.
RT-PCR 
Total RNA was extracted from the liver and adipose 
tissue around the left kidney using TRIzol reagent ac-
cording to the manufacturer’s instructions (Promega, 
Carlsbad, CA). A semiquantitative real-time PCR (RT-
PCR) was performed with Line-Gene (Toyobo, Tokyo) 
and SYBR Green I (Roche, Basel, Switzerland). The 
detection was executed at the extension reaction stage in 
each cycle. 
 The primer sets for RBP4, HFABP, CFABP, MCP1, 
CCR2 and beta-actin mRNA were all synthesized by 
Hokkaido System Science (Sapporo, Japan). The se-
quence of each primer is listed in Table 1. Using the 
2-ΔΔCT method, mRNA expression was semi-quantita-
tively measured as a relative amount of each target RNA 
to a known housekeeping gene (beta-actin) expression 
level.26, 27
 
Table 1. The sequence of each PCR primer
 Gene Primer
 RBP Forward 5'-gacaaggctcgtttctctgg-3'
 Reverse 5'-gactcgtcccttggctgtag-3'
H-FABP Forward 5'-ctagcatgagggaagcaagg-3'
 Reverse 5'-tgcttcatccagacaagtgg-3'
C-FABP Forward 5'-gggctggctcttaggaagat-3'
 Reverse 5'-aaaacacggtcgtcttcacc-3'
MCP1 Forward 5'-ctgtagcatccacgtgctgt-3'
 Reverse 5'-tgctgctggtgattctcttg-3'
CCR2 Forward 5'-gatcctgcccctacttgtca-3'
 Reverse 5'-agatgagcctcacagcccta-3'
Beta-actin Forward 5'-gtagccatccaggctgtgtt-3'
 Reverse 5'-ccctcagatgggcacagt-3'
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Fig. 1. Histopathological examination of liver. 
A: Fatty degeneration (steatosis) of the liver is observed in the high-cholesterol diet-fed (H, HA, HB, HC and HE) groups, but not in 
Group C in hematoxylin-eosin stained tissues. Fatty changes increase with time to a greater extent in Group H than Groups HA, HB, 
HC and HE. 
B:  Oil red O staining reveals more lipid droplets (stained red) to be accumulated in vacuoles in Group H than other groups. 
6W, 6 weeks; 12W, 12 weeks. C, control: standard diet for 6 and 12 weeks (n = 5). H: high-cholesterol diet for 6 and 12 weeks (n = 5). HA: 
high-cholesterol diet with Boiogito for 6 and 12 weeks (n = 5). HB: high-cholesterol diet with Bofutsushosan for 6 and 12 weeks (n = 5). 
HC: high-cholesterol diet with Keishibukuryogan for 6 and 12 weeks (n = 5). HE: high-cholesterol diet with ezetimibe for 6 and 12 weeks (n 
= 5). Bars express 25 μm.
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Immunohistochemical studies
During the immunohistochemical analyses, 4% form-
aldehyde-fixed aorta tissue specimens were processed. 
The following monoclonal antibody was used: anti-
ICAM-1 (Abcam, Cambridge, United Kingdom). As a 
negative control, tissues were stained without the prima-
ry antibody. The optical densities were measured by Im-
age-Pro Plus version 6.0 software (Media Cybernetics, 
Rockville, MD).
 
Statistical analyses 
The data are expressed as the mean ± SEM. For the 
continuous variables, differences in responses among 
groups were compared using Mann-Whitney’s U test for 
non-parametric variables by SPSS 11.0 J (SPSS Japan, 
Tokyo). P < 0.05 was considered statistically significant.
RESULTS
Histological examination of liver tissues 
As Fig. 1 shows, the fatty degeneration (steatosis) of liver 
was observed in the high-cholesterol diet-fed (H, HA, 
HB, HC and HE) groups, but not in Group C. These 
changes comprising tiny and large vacuoles as well as 
pleomorphic nuclei were more prominent in Groups 
HA, HB, HC and HE than in Group H (Fig. 1A). Oil red 
O staining revealed that the livers in all high-cholesterol 
diet supplemented groups were filled with microvesicu-
lar or macrovesicular fat deposits; they were depicted as 
reddish deposits (Fig. 1B). Overall, fatty liver changes 
were more prominent in Group H than Groups HA, HB, 
HC and HE (× 400).
 
Histological examination of adipose tissue 
As Fig. 2 shows, the larger fat cells were observed in 
the high-cholesterol diet-fed (H, HA, HB, HC and HE) 
groups, but not in Group C. It was more prominent in 
Group H than Groups HA, HB, HC and HE (× 400). 
 
Body and liver weights 
As Table 2 shows, there were no significant differences 
in the baseline of body weights at the beginning of the 
experiment. The body weights had no significant dif-
ferences during the experiment too. Liver weights were 
significantly lower in Group HE than Group H after 6 
and 12 weeks (P < 0.05).
 
Fig. 2. Histopathological examination of adipose tissue. 
The larger fat cells are observed in the high-cholesterol diet-fed (H, HA, HB, HC and HE) groups, but not in Group C (56.13 ± 11.51 and 
64.88 ± 13.96 μm after 6 and 12 weeks, respectively) in hematoxylin-eosin stained tissues. Fat cells change with time to a greater extent in 
Group H (97.00 ± 20.14 and 104.63 ± 22.56 μm after 6 and 12 weeks, respectively) than Groups HA, HB, HC and HE (55.63 ± 5.85 and 
78.88 ± 16.34 μm, 75.63 ± 11.53 and 78.13 ± 16.47 μm, 74.63 ± 13.94 and 88.13 ± 8.58 μm, 74.38 ± 13.21 and 83.13 ± 16.63 μm after 6 and 
12 weeks, respectively). Bars express 50 μm.
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Table 2. Body and liver weights
  Group C Group H Group HA Group HB Group HC Group HE
 Body weight  (g)
   0W 233.1 ± 6.6 233.5 ± 6.6 235.9 ± 6.7 237.2 ± 9.4 237.1 ± 7.8 236.1 ± 6.7
   6W 402.8 ± 15.9 398.5 ± 23.2 390.0 ± 21.9 392.4 ± 8.6 395.9 ± 23.9 385.8 ± 24.6
 12W 448.6 ± 14.0 477.1 ± 15.5* 461.6 ± 26.1 457.6 ± 32.7 470.2 ± 32.9 453.3 ± 29.2
Liver weight (g)
   6W 10.1 ± 0.9 15.0 ± 0.8* 15.5 ± 2.6 15.8 ± 1.4 14.9 ± 1.1 10.8 ± 1.0†
 12W 12.5 ± 3.5 19.0 ± 3.1* 18.9 ± 1.5 19.9 ± 2.4 19.9 ± 2.2 12.1 ± 1.1†
 0W, 0 weeks; 6W, 6 weeks; 12W, 12 weeks. C, control: standard diet for 6 and 12 weeks (n = 5). H: high-cholesterol diet for 6 and 12 weeks (n 
= 5). HA: high-cholesterol diet with Boiogito for 6 and 12 weeks (n = 5). HB: high-cholesterol diet with Bofutsushosan for 6 and 12 weeks (n 
= 5). HC: high-cholesterol diet with Keishibukuryogan for 6 and 12 weeks (n = 5). HE: high-cholesterol diet with ezetimibe for 6 and 12 
weeks (n = 5). *P < 0.05 versus Group C. †P < 0.05 versus Group H. Data are expressed as the mean ± SEM. 
Table 3. Blood chemistry and cholesterol concentrations
  Group C Group H Group HA Group HB Group HC Group HE
 TC (mg/dL)   6W 55.5 ± 15.2 68.2 ± 6.8 67.4 ± 13.7 65.4 ± 9.8 68.6 ± 13.8 78.5 ± 12.4
 12W 56.6 ± 13.0 78.8 ± 5.4* 73.7 ± 10.4 75.2 ± 12.0 70.5 ± 12.0 73.2 ± 3.5
HDL-C (mg/dL)   6W 18.0 ± 2.6 21.0 ± 2.2 20.4 ± 4.5 19.4 ± 2.9 20.0 ± 3.2 17.5 ± 2.7
 12W 16.0 ± 2.6 22.2 ± 0.8* 22.7 ± 3.2 23.8 ± 3.1 20.0 ± 3.4 19.4 ± 1.1
LDL-C (mg/dL)   6W 5.6 ± 1.1 8.4 ± 1.7* 8.6 ± 2.3 8.0 ± 1.9 8.8 ± 2.6 8.8 ± 2.2
 12W 6.0 ± 1.4 11.8 ± 0.8* 9.0 ± 1.7† 9.8 ± 2.7 10.5 ± 4.4 8.0 ± 1.2†
TG (mg/dL)   6W 31.5 ± 7.5 34.4 ± 11.2 28.0 ± 17.1 18.2 ± 3.9† 21.8 ± 8.8 25.0 ± 8.0
 12W 29.2 ± 9.2 26.4 ± 4.7 22.7 ± 6.9 24.0 ± 7.9 19.8 ± 5.4 16.4 ± 7.0†
BS (mg/dL)   6W 109.4 ± 7.7 99.6 ± 7.2 112.8 ± 8.8† 105.4 ± 6.6 110.8 ± 12.0 112.6 ± 10.5
 12W 102.8 ± 6.1 112.0 ± 11.0 111.3 ± 20.0 114.8 ± 17.8 99.2 ± 7.6 101.2 ± 9.2
Cr (mg/dL)   6W 0.30 ± 0.03 0.30 ± 0.04 0.35 ± 0.06 0.35 ± 0.05 0.34 ± 0.04 0.34 ± 0.07
 12W 0.32 ± 0.04 0.35 ± 0.03 0.34 ± 0.02 0.36 ± 0.11 0.34 ± 0.03 0.32 ± 0.03
TBil (μmol/L)   6W 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.03 ± 0.02
 12W 0.04 ± 0.02 0.03 ± 0.02 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.01
ALT (U/L)   6W 60.0 ± 11.7 72.2 ± 11.4* 71.8 ± 18.2 61.3 ± 10.2 93.6 ± 17.1 111.0 ± 11.1†
 12W 53.4 ± 3.0 148.7 ± 25.7* 79.0 ± 17.4† 104.3 ± 26.1† 79.2 ± 18.5† 109.7 ± 25.8
ALP (U/L)   6W 413.0 ± 22.6 497.8 ± 24.8 377.5 ± 31.2† 399.0 ± 20.1† 450.0 ± 35.6 519.0 ± 34.9
 12W 331.0 ± 28.5 432.7 ± 31.7* 334.3 ± 32.1† 337.0 ± 25.5† 283.3 ± 27.1† 514.8 ± 17.8†
 6W, 6 weeks; 12W, 12 weeks. ALP, alkaline phosphatase; ALT, alanine aminotransferase; BS, blood sugar; Cr, creatinine; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TBil, total bilirubin; TC, total cholesterol; TG, triglyceride. 
*P < 0.05 versus Group C. †P < 0.05 versus Group H. Data are expressed as the mean ± SEM. 
Fig. 3. Intercellular adhesion molecule-1 (ICAM-1) and retinol-binding protein 4 (RBP4) concentration in serum. ICAM-1 and RBP4 
concentrations in control, standard diet group (C, n = 5), high-cholesterol diet group (H, n = 5), high-cholesterol diet with BOT group (HA, 
n = 5), high-cholesterol diet with BTS group (HB, n = 5), high-cholesterol diet with KBG group (HC, n = 5) and high-cholesterol diet with 
ezetimibe group (HE, n = 5) for 6 and 12 weeks. *P < 0.05 versus Group C. †P < 0.05 versus Group H.
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Blood chemistry and cholesterol concentrations 
After 6 weeks of the experiment, the concentration of 
LDL-C in Group H (8.4 ± 1.7 mg/dL) was significantly 
elevated compared to the concentration in Group C (5.6 
± 1.1 mg/dL) (P < 0.05). After 12 weeks, the concentra-
tion of TC in Group H (78.8 ± 5.4 mg/dL) was signifi-
cantly elevated compared with it in Group C (56.6 ± 
Fig. 4. Changes in mRNA expression with time in liver and adipose tissue. Levels of RBP4, HFABP, CFABP, MCP1 and CCR2 against 
beta-actin mRNA expression are shown in the above histograms. The left-side graphs show the expression in liver. The right-side graphs 
show the expression in adipose tissue around the left kidney.
13.0 mg/dL) (P < 0.05). The concentration of HDL-C in 
Group H (22.2 ± 0.8 mg/dL) was significantly elevated 
compared with it in Group C (16.0 ± 2.6 mg/dL) (P < 0.05). 
The concentration of LDL-C elevated to a greater extent 
in Group H (11.8 ± 0.8 mg/dL) than that in Groups HA 
and HE (9.0 ± 1.7 and 8.0 ± 1.2 mg/dL, respectively) (P 
< 0.05). The concentration of ALT in Group H (148.7 ± 
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25.7 U/L) was significantly elevated compared with it in 
Group C (53.4 ± 3.0 U/L) (P < 0.05). It was decreased in 
Groups HA, HB and HC (79.0 ± 17.4, 104.3 ± 26.1, 79.2 
± 18.5 U/L, respectively) than in Group H (P < 0.05). 
The concentration of ALP in Group H (432.7 ± 31.7 U/
L) was significantly elevated compared with it in Group 
C (331.0 ± 28.5 U/L) (P < 0.05). It was lower in Groups 
HA, HB and HC (334.3 ± 32.1, 337.0 ± 25.5, 283.3 ± 27.1 
U/L, respectively) than in Group H (P < 0.05) (Table 3). 
 
ICAM-1 and RBP4 in serum 
ICAM-1 concentrations were increased in Group H 
compared to Groups C, HA, HB and HE after 12 weeks 
(Fig. 4, P < 0.05). RBP4 concentrations were increased 
in Group H compared to the other groups includ-
ing Groups C, H, HA and HE after 6 and 12 weeks 
(Fig. 3, P < 0.05).
 
mRNA expression in liver and adipose tissue 
Figure 4 demonstrates the changes of mRNA expression 
in liver and adipose tissue round the left kidney of rats 
Fig. 5.  Immunohistochemistry expression of ICAM-1 in  aorta. 
A: Seldom ICAM-1 immunostaining (red-brown deposits indicate positive staining) is found on the whole layers of abdominal aortas in 
Group C. Bars express 25 μm. 
B: Mean optical density values of ICAM-1. The photographs generated were quantitatively analyzed the optical density of ICAM-1 with 
Image-Pro Plus version 6.0 software. *P < 0.05 versus Group C. †P < 0.05 versus Group H.
for 6 and 12 weeks. 
 RBP4 mRNA expression in liver in Group H was 
significantly increased compared to that in Groups C, 
HA and HE after 6 and 12 weeks (P < 0.05). HFABP 
mRNA expression in Group H was significantly in-
creased compared to that in Groups C, HA and HE after 
12 weeks (P < 0.05). Compared with the other groups, 
the mRNA expression of CFABP in liver in Group H 
were higher than that in Groups C, HA, HB and HE at 
12 weeks (P < 0.05), whereas they were not obvious at 
6 weeks. Compared with the other groups, the mRNA 
expression of MCP1 in liver in Group H remained high 
during the entire experiment, especially after 12 weeks 
(P < 0.05). The expression of CCR2 in liver in Groups 
HA, HB, HC (at 6 and 12 weeks) and HE (at 12 weeks) 
were lower than that in Group H (P < 0.05).
 A down-regulation of RBP4 mRNA expression in 
Group H appeared in adipose tissue around the left kid-
ney after 12 weeks; even it was higher in Group H than 
that in Groups C, HA and HE (P < 0.05). The mRNA 
expression of HFABP was higher in Group H than that 
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in Groups C, HA, HE (at 6 and 12 weeks) and HB (at 
12 weeks) (P < 0.05). CFABP mRNA expression had 
no significant difference during the whole experiment 
among all the groups. The expression of MCP1 in adi-
pose tissue in Groups HA, HB, HE (at 6 and 12 weeks) 
and HC (at 12 weeks) was lower than that in Group H (P 
< 0.05). The CCR2 mRNA expression in Group H was 
higher than that in Groups HA, HB and HC (P < 0.05).
 
ICAM-1immunostaining expression in aorta  
As shown in Fig. 5, after 12 weeks, little ICAM-1 
immunostaining (red-brown deposits indicate posi-
tive staining) was found on the whole layers of ab-
dominal aortas in Group C. Significantly positive 
ICAM-1 immunostaining was observed in Group H 
and mainly localized on the endothelial layers. Posi-
tive ICAM-1 immunostaining was also observed in 
Groups HA, HB, HC and HE, but less than Group H. 
While ICAM-1 immunoreactivities were very weak 
in Groups HA, HB, HC and HE, the positive area and 
the strength of ICAM-1 stainings was markedly lower 
than those in Group H (× 400).
 
Blood pressure and heart rate 
No significant changes in systolic or diastolic blood 
pressure and heart rates were observed during the ex-
periment. 
 
DISCUSSION
Hypercholesterolemia is one of major risk factors 
contributing to cardiovascular diseases.3, 4 Patients 
with NAFLD have a high risk of CVD, too.5 Elevated 
concentrations of plasma TC and LDL-C as well as 
reduced concentration of HDL-C are negative risk fac-
tors for CVD is well documented.28–30 Lipid-lowering 
drugs, such as statins, hydroxyl-methylglutaryl-coen-
zyme A reductase inhibitors can well reduce LDL-C 
and increase HDL-C. Adverse reactions such as rhab-
domyolysis and hepatitis were sometimes caused by 
them. Therefore, minimizing the side effects of lipid-
lowering drugs is also very important. The mechanism 
of Kampo formula is to restore the balance of the body. 
It is a safe way to achieve the balance between LDL-C 
and HDL-C concentrations. In this study, we observed 
the effect of Kampo formulas (BOT, BTS, KBG) on 
the progression of hypercholesterolemia and fatty 
liver induced by high-cholesterol diet in rats. LDL-C, 
ALT and ALP concentrations in the serum of rats fed 
high-cholesterol diet with BOT decreased. ALT (at 6 
weeks) and ALP (at 12 weeks) concentrations in Group 
HE was significantly elevated compared with that in 
Group H. The reason is still unknown. The steatosis 
of liver and hypertrophy of fat cells caused by high-
cholesterol diet could be alleviated by BOT, BTS and 
KBG as shown by histopathological examinations.
 Retinol-binding protein 4 (RBP4), a protein secret-
ed by hepatocytes (80%) and adipose tissue (20%), is a 
21-kDa protein that facilitates the transport of retinol 
through the circulation to peripheral tissues.11 It plays 
a key role in the control of metabolic and proliferative 
cell functions,31 including steatogenesis.32 Recently, 
the role of adipokines, specifically RBP4 in the patho-
genesis of obesity-related diseases is widely being 
discussed.33–36 Many studies have reported the rela-
tionship between RBP4 and obesity as well as its re-
lated complications.35–37 Recent studies demonstrated 
that RBP4 levels were increased in obese and insulin-
resistant humans and mouse models.38–41 Stefan et al. 
found a direct relation between hepatic fat content and 
blood levels of RBP4 in healthy subjects, too.42 It has 
been reported that RBP4 mRNA expression can be 
up-regulated in liver and adipose tissue of rats with 
high cholesterol diet for 12 weeks.11 In our experiment, 
RBP4 expression in liver and adipose tissue of rats 
fed a high-cholesterol diet as well as the expression in 
serum were up-regulated. BOT and ezetimibe shows 
greater effect to decrease the level of RBP4 mRNA 
expression in liver and adipose tissue, the serum ex-
pression of RBP4 can also be decreased by BOT and 
ezetimibe.  
 HFABP is a member of a family of binding pro-
teins with distinct tissue distributions and diverse 
roles in fatty acid metabolism, trafficking, and signal-
ing.43 It is a low molecular-weight cytoplasmic protein 
that is abundant in the myocardium44 and produced 
by skeletal muscle,45 cardiomyocytes, kidney distal 
tubular cells46 and specific parts of the brain.47, 48 
HFABP mRNA expression has been reported to be 
up-regulated in livers of rats fed high-cholesterol diet 
for 28 days.11 In our study, this phenomenon was also 
demonstrated. HFABP mRNA expression in the liver 
and adipose tissue of high-cholesterol diet groups was 
significantly increased compared to the control group 
after 12 weeks. 
 CFABP was originally identified as being over-
expressed in the psoriatic skin.49, 50 It is typical of the 
FABP family and binds long-chain fatty acids with 
high affinity49, 51 and were thought to play a important 
role in the storage and transport of fatty acids.50, 52, 53 
CFABP was reported to be up-regulated after 12 
weeks in liver and adipose tissue of high-cholesterol 
diet rats.11 Here, the mRNA expression of CFABP in 
liver of high-cholesterol diet rats were higher after 12 
weeks while there were no significant differences be-
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tween groups in adipose tissue. BOT, BTS and ezeti-
mibe can down-regulate the CFABP mRNA expres-
sion in liver.
 BOT, BTS and KBG are all used as anti-obesity 
medications in Japan.54 BOT is used for people with a 
solid build and thick abdominal subcutaneous fat.54 It 
could decrease the mouse body weight, fat accumula-
tion, TC and triglyceride level, but cannot influence 
fasting blood glucose levels or insulin levels.22 BTS is 
used for patients with flabby constitution and prone-
ness to fatigue.54 It can decrease food intake, body 
weight, blood pressure, white adipose tissue weight 
and ameliorate the adipocytokine dysregulation in 
white adipose tissue.55 KBG is commonly used for 
women with sudden weight gain in menopause and 
could led to a reduction in blood cholesterol.54, 56 Ac-
cording to these reports, even BOT, BTS and KBG are 
all used in the treatment of obesity, they are suitable 
for different situations. In our study, BOT has a bet-
ter effect on the progression of hypercholesterolemia 
and fatty liver induced by high-cholesterol diet in rats. 
Ougi and Ginger are the key components of BOT, 
and it has been reported that Ougi and Ginger of BOT 
contribute greatly to the beneficial effects on abnormal 
lipid metabolism.22 Matsuda et al. also found that Gin-
ger tends to improve lipid metabolism.24 Wang et al. 
reported that Ougi could significantly reduced plasma 
levels of TC and LDL-C and improved the atheroscle-
rosis profile.57 These results partly explain the present 
findings. We speculate that inhibition of lipid absorp-
tion might contribute to the effect of BOT.22 However, 
the mechanisms of BTS and KBG are still unknown. 
 Inflammatory factors play important roles in 
NAFLD and atherosclerosis progression.8 MCP1 is 
an important inflammatory chemokine that can be 
produced by a variety of cells including vascular endo-
thelial cells, vascular smooth muscle cells, monocytes 
and other cells. It is a member of the CC chemokine 
family.58, 59 Plasma concentration of MCP1 increases 
with obesity.60, 61 CCR2 is a receptor of MCP1 and 
can help MCP1 to accomplish its effect.62 Dietary cho-
lesterol can induce the MCP1 gene expression,14 and 
CCR2 expression was increased in hypercholesterol-
emic patients compared with normocholesterolemic 
controls.15, 63 In our experiment, compared with the 
other groups, the mRNA expression of MCP1 and 
CCR2 in both liver and adipose tissue in Group H re-
mained high level during the entire experiment, espe-
cially after 12 weeks. BOT, BTS, KBG and ezetimibe 
can down-regulate the MCP1 and CCR2 expression. 
This effect of BOT, BTS and KBG is direct or indirect 
through inhibition of cholesterol metabolism is still 
unknown.
 ICAM-1, a member of the immunoglobulin super-
family, is one of the markers of endothelial cell activa-
tion. It plays an important role in neutrophil migration 
and adhesion of endothelial cells64 and is partly involved 
in the whole process of monocyte adhesion, migration 
and transformation.16 This migration is one of the earliest 
events in the atherosclerotic process.65 ICAM-1 was up-
regulated in neointimal and medial smooth muscle cells 
after vascular injury.66 Sekiya et al. reported that KBG 
could prevent the progression of atheromatous plaque, 67 
but no literature could prove the effect of BOT and BTS 
on preventing atherosclerosis. In our experiment, serum 
ICAM-1 concentration and immunostaining expression 
were increased in Group H after 12 weeks. BOT, BTS, 
KBG and ezetimibe can down-regulate it. We speculate 
that down-regulated ICAM-1 may be one of the mecha-
nisms of BOT, BTS and KBG to prevent atherosclerosis.
 Overall, BOT has a protective effect on the progres-
sion of hypercholesterolemia and fatty liver induced by 
high-cholesterol diet in rats and more effective than BTS 
and KBG. Ezetimibe has the similar effect on lipid relat-
ed factors, such as LDL-C, RBP4, HFABP and CFABP. 
However, the anti-inflammatory (MCP1, CCR2) and 
anti-arteriosclerotic (ICAM-1) effects of BOT are more 
potent than ezetimibe. This may be a guide on clinical 
use. The mechanism is still uncertain and further studies 
should be designed.
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